Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial

CONCLUSION: The study demonstrated that MVA-BN-WEV is well tolerated, induces immune responses, and is suitable for further development.CLINICAL TRIAL REGISTRY NUMBER: NCT04131595.PMID:38494412 | DOI:10.1016/j.vaccine.2024.03.011

Source: Vaccine - March 17, 2024 Category: Allergy & Immunology Authors: Carlos Fierro Heinz Weidenthaler Sanja Vidojkovic Darja Schmidt Zarina Gafoor Daria Stroukova Susan Zwiers Jutta M üller Ariane Volkmann Source Type: research